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OBJECTIVE—Recent data suggested that sex hormone–bind-
ing globulin (SHBG) levels decrease when fat accumulates in the
liver and that circulating SHBG may be causally involved in the
pathogenesis of type 2 diabetes in humans. In the present study,
we investigated mechanisms by which high SHBG may prevent
development to diabetes.
RESEARCH DESIGN AND METHODS—Before and during a
9-month lifestyle intervention, total body and visceral fat were
precisely measured by magnetic resonance (MR) tomography
and liver fat was measured by
1H-MR spectroscopy in 225
subjects. Insulin sensitivity was estimated from a 75-g oral
glucose tolerance test (ISOGTT) and measured by a euglycemic
hyperinsulinemic clamp (ISclamp, n  172). Insulin secretion was
measured during the OGTT and an ivGTT (n  172).
RESULTS—SHBG levels correlated positively with insulin sen-
sitivity (ISOGTT, P  0.037; ISclamp, P  0.057), independently of
age, sex, and total body fat. In a multivariate model, these
relationships were also signiﬁcant after additional adjustment for
levels of the adipokine adiponectin and the hepatokine fetuin-A
(ISOGTT, P  0.0096; ISclamp, P  0.029). Adjustment of circulat-
ing SHBG for liver fat abolished the relationships of SHBG with
insulin sensitivity. In contrast, circulating SHBG correlated neg-
atively with fasting glycemia, before (r  0.17, P  0.009) and
after (r  0.14, P  0.04) adjustment for liver fat. No correla-
tion of circulating SHBG with adjusted insulin secretion was
observed (OGTT, P  0.16; ivGTT, P  0.35). The SNP rs1799941
in SHBG was associated with circulating SHBG (P  0.025) but
not with metabolic characteristics (all P  0.18).
CONCLUSIONS—Possible mechanisms by which high circulat-
ing SHBG prevents the development of type 2 diabetes involve
regulation of fasting glycemia but not alteration of insulin
secretory function. Diabetes 59:3167–3173, 2010
R
ecently, two studies applying the Mendelian
randomization approach, an elegant tool to
study causal relationships between plasma pa-
rameters and traits in humans (1), suggested
that circulating sex hormone–binding globulin (SHBG)
may be involved in the pathogenesis of type 2 diabetes in
men and women (2,3). Because circulating SHBG regu-
lates biological action and signaling of sex hormones (4),
these data strengthen the notion that sex hormones play
an important role in the pathogenesis of the disease. So
far, however, results from several studies revealed that
this ﬁeld of research is very complex. Whereas high
testosterone levels were found to be associated with
insulin resistance, glucose intolerance, and increased risk
of type 2 diabetes in women, in men high testosterone
levels appear to protect from insulin resistance and diabe-
tes. In contrast, in both sexes, although not consistent
among all studies, high estradiol levels were associated
with elevated insulin resistance and increased risk of type
2 diabetes (5,6).
For relationships of circulating SHBG with insulin sen-
sitivity and risk of type 2 diabetes, the data were more
consistent among sexes. Low plasma levels of SHBG were
found to be similarly strongly associated with insulin
resistance and increased risk of type 2 diabetes, in men
and in women in most (7–11), but not in all, studies
(12–15).
The question now is, besides genetic variability in
SHBG, which parameters involved in the natural history of
type 2 diabetes regulate plasma levels of SHBG? Studies
indicated that high insulin levels decrease the release of
SHBG from hepatocytes (16,17), which represent the
major source of SHBG biosynthesis (18). However, Selva
et al. provided convincing evidence that expression of
SHBG in hepatocytes could be suppressed by glucose or
fructose, strong inducers of hepatic lipogenesis (19), but
not by insulin (20). This is in agreement with human
studies showing that low circulating SHBG was not asso-
ciated with elevated insulin levels (21) but was associated
with obesity and dyslipidemia, conditions that are strongly
associated with fatty liver in humans (22–29). On the basis
of the data from Selva et al. (20), we hypothesized that
speciﬁcally fatty liver may be associated with low circu-
lating SHBG in humans, and we could recently support
this in a small study (30).
Because of the unexpected ﬁnding of no signiﬁcant
relationships between genetic variants in SHBG and met-
abolic traits in the study by Perry et al. (3), in the present
study we investigated mechanisms behind the association
between low SHBG levels and increased risk of type 2
diabetes in our precisely phenotyped subjects. Therefore,
we additionally genotyped them for a variant that was
found to be strongly associated with plasma SHBG levels
and the risk of type 2 diabetes (3).
RESEARCH DESIGN AND METHODS
Caucasians from the southern part of Germany participated in the ongoing
Tu ¨bingen Lifestyle Intervention Program (TULIP) (31–33). Individuals were
included in the study when they fulﬁlled at least one of the following criteria:
a family history of type 2 diabetes, a BMI  27 kg/m
2, or previous diagnosis of
impaired glucose tolerance or gestational diabetes. In a small pilot study, we
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visceral fat, and liver fat in a total of 114 subjects (30). One hundred seven
subjects from that study had these measurements and blood samples, both at
baseline and after 9 months of lifestyle intervention, and were also included in
the present study. We subsequently included another set of 118 subjects, who
met the aforementioned requirements, resulting in a total of 225 subjects in
the present study.
Subjects were considered healthy according to a physical examination and
routine laboratory tests. As assessed by means of a standard questionnaire,
the participants had no history of liver disease such as hepatitis and did not
consume more than two alcoholic drinks per day. Informed written consent
was obtained from all participants, and the local medical ethics committee
approved the protocol.
Lifestyle intervention. After the baseline measurements, individuals under-
went dietary counseling and had up to ten sessions with a dietitian. Counsel-
ing was aimed to reduce body weight, intake of calories, and particularly
intake of calories from fat, as well as to increase intake of ﬁbers. No speciﬁc
recommendations regarding protein intake were given. Individuals were
asked to perform at least3ho fmoderate sports per week. Aerobic endurance
exercise (e.g., walking or swimming) with an only moderate increase in the
heart rate was encouraged. Participants were seen by the staff on a regular
basis to ensure that these recommendations were accomplished. Further-
more, all subjects completed a standardized and validated questionnaire to
estimate physical activity, and a habitual physical activity score was
calculated.
Body fat distribution and liver fat. Waist circumference was measured at
the midpoint between the lateral iliac crest and the lowest rib. Furthermore,
we measured total and visceral fat with an axial T1-weighed fast spin echo
technique with a 1.5 T whole-body imager (Magnetom Sonata, Siemens
Healthcare) (34). Volunteers were in prone position, and images were
recorded from ﬁngers to toes with a slice thickness of 10 mm and a gap
between slices of 10 mm. Segmentation of images was performed by semiau-
tomatic thresholding based on a Matlab routine (Mathworks, Inc.). Visceral fat
was quantiﬁed in 16–21 slices (depending on the size of the volunteer)
between femoral heads and diaphragm, not differentiating between intra- and
retroperitoneal fat, by manual delineation of the visceral compartment. Fat
volume from images was calculated by multiplying the in-plane pixel dimen-
sions with the slice thickness and the number of pixels classiﬁed as fat.
Volumes between contiguous slices are calculated by simply doubling the
volume of the adjacent slice. Liver fat was measured by localized
1HMR
spectroscopy as previously described (34).
Maximal aerobic capacity. Individuals underwent a continuous, incremental
exercise test to volitional exhaustion using a cycle ergometer. The cycle
ergometer test was performed on an electromagnetically braked cycle er-
gometer (Ergometrics 800 S; Ergoline, Bitz, Germany). Oxygen consumption
was measured using a spiroergometer (MedGraphics System Breese Ex 3.02
A; MedGraphics). Maximal aerobic capacity (VO2max) is expressed as VO2
(ml/min) per kg body weight (ml  min
1  kg
1).
Oral glucose tolerance test. All individuals underwent a 75 g oral glucose
tolerance test (OGTT). We obtained venous plasma samples at 0, 30, 60, 90,
and 120 min for determination of plasma glucose and insulin. Glucose
tolerance was determined according to the 1997 World Health Organization
diagnostic criteria (35).
Euglycemic hyperinsulinemic clamp. Insulin sensitivity was determined
with a primed insulin infusion at a rate of 40 mU  m
2  min
1 f o r2ha s
previously described (34).
Analytical procedures. Blood glucose was determined using a bedside
glucose analyzer (glucose-oxidase method; YSI, Yellow Springs Instruments,
Yellow Springs, OH). Plasma insulin and C-peptide were determined by
microparticle enzyme immunoassays (ADVIA Centaur, Siemens Healthcare
Diagnostics, Eschborn, Germany). Fasting plasma levels of adiponectin were
determined with enzyme-linked immunosorbent assays (ELISA, Linco Re-
search, Inc., St Charles, MO). Fasting plasma levels of fetuin-A were measured
by an immunoturbidimetic method (BioVendor Laboratory Medicine, Modreci,
Czech Republic). Serum SHBG levels were measured using the fully auto-
mated solid-phase, chemiluminescent immunoassay IMMULITE 2,500 (Sie-
mens Healthcare Diagnostics, Eschborn, Germany).
Calculations. The insulin sensitivity index measured during the clamp (in
mol  kg
1  min
1  pM
1) was calculated as the mean infusion rate of
glucose (in mol  kg
1  min
1) necessary to maintain euglycemia during the
last 40 min of the euglycemic hyperinsulinemic clamp divided by the steady-
state plasma insulin concentration. The latter was the mean insulin concen-
tration at 100, 110, and 120 min of the clamp. Insulin sensitivity from the OGTT
was estimated as proposed by Matsuda and DeFronzo (36). The insulinogenic
index was assessed from the OGTT as follows: (insulin at 30 min  insulin at
0 min)/(glucose at 30 min  glucose at 0 min). Insulin secretion during the
intravenous GTT (IVGTT) was assessed as the sum of C-peptide levels
and insulin levels, respectively, during the ﬁrst 10 min after glucose
administration.
Genotyping. For genotyping, DNA was isolated from whole blood using a
commercial DNA isolation kit (NucleoSpin, Macherey & Nagel, Du ¨ren, Ger-
many). The SNP rs1799941 in SHBG (37,38), which was found to be associated
with circulating SHBG and type 2 diabetes (3), was genotyped using TaqMan
assay (Applied Biosystems, Foster City, CA, USA).The TaqMan genotyping
reaction was ampliﬁed on a GeneAmp PCR system 7,000 (50°C for 2 min, 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min), and
ﬂuorescence was detected on an ABI Prism sequence detector (Applied
Biosystems, Foster City, CA, USA). The TaqMan assay was validated by direct
sequencing of the SNP in 50 subjects, and both methods gave identical results.
The genotyping success rate for the SNP rs1799941 was 99.9%, and rescreen-
ing of 3.3% of the subjects with the TaqMan assay gave 100% identical results.
Statistical analyses. Data that were not normally distributed (e.g., liver fat,
circulating SHBG, insulin sensitivity, body fat distribution; Shapiro-Wilk W
test) were logarithmically transformed. Differences between baseline and
follow-up were tested using the matched-pairs t test. Univariate associations
between parameters were tested using Pearson correlation analyses. To
adjust the effects of covariates and identify independent relationships, multi-
variate linear regression analyses were used. To test the effect of the genotype
on the metabolically relevant parameters, the parameter to be considered was
set as the dependent variable. The genotype was included in both analyses as
an independent nominal variable. The statistical software package JMP 5.1
(SAS Institute Inc, Cary, NC, USA) was used.
RESULTS
Characteristics of all 225 subjects. Anthropometrics
and metabolic characteristics of the 225 subjects at base-
line (Table 1) covered a wide range that was particularly
large for total body fat, visceral fat, liver fat, insulin
sensitivity, and circulating SHBG. A total of 66 subjects
had fatty liver (liver fat  5.56%) (39). Circulating SHBG
was lower in males than females (means  SE; 24.8  1.1
vs. 56.2  4.3 mM, P  0.0001) and did not correlate
signiﬁcantly with age (r  0.01, P  0.17) or VO2max (r 
0.10, P  0.16).
During the lifestyle intervention, measures of total and
visceral adiposity and liver fat decreased and physical
activity and VO2max increased (Table 1). A decrease was
also found for fasting and 2-h glycemia and insulinemia.
While insulin sensitivity increased, measures of insulin
secretion remained unchanged. High-sensitivity C-reactive
protein levels decreased, and adiponectinemia increased.
Circulating SHBG also increased. Regarding dietary in-
take, at baseline circulating SHBG correlated negatively
with total energy intake (r  0.28, P  0.0001) but not
with percentage of carbohydrate, fat, or protein intake.
During the intervention, a trend for a larger increase in
circulating SHBG with larger decrease in carbohydrate
intake was observed (r  0.10, P  0.13).
Relationships of circulating SHBG with total body
fat, visceral fat, and liver fat at baseline and during
the lifestyle intervention in 118 subjects. First we
tested whether we can replicate our previous ﬁndings of a
strong and independent relationship of circulating SHBG
with liver fat in the 118 subjects that were not included in
our previous analysis about relationships of circulating
SHBG with total body, visceral, and liver fat (30). In the
118 subjects, circulating SHBG adjusted for sex and age
correlated negatively with total body, visceral, and liver fat
(Table 2). In multivariate linear regression analyses includ-
ing age, sex, and liver, total body, and visceral fat, liver fat
(F-value  11, P  0.0016) was the strongest determinant
of circulating SHBG followed by sex (F-value  6, P 
0.017), while total body (F-value  1, P  0.62) and
visceral fat (F-value  1, P  0.61) were not independent
determinants.
On the basis of the strong correlations between liver fat
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in circulating SHBG was speciﬁcally found in subjects in
whom a large decrease in liver fat was observed. Indeed,
there was a strong correlation between change in liver fat
and change in circulating SHBG (r  0.37, P  0.0001).
Negative correlations, albeit weaker in magnitude, were
also found between changes in circulating SHBG with total
body (r  0.28, P  0.0018) and visceral fat (r  0.23,
P  0.011). In a multivariate analysis, change in liver fat
correlated with change in circulating SHBG, indepen-
dently of sex, age, and changes in total body and visceral
fat (r  0.29, P  0.0023). In this model, changes in total
body and visceral fat did not correlate with changes in
circulating SHBG anymore (both P  0.24).
Relationship between circulating SHBG and meta-
bolic characteristics in 225 subjects. We next investi-
gated whether circulating SHBG correlated with
metabolic traits in 225 subjects. SHBG levels were
negatively associated with fasting glycemia (r  0.17,
P  0.009) but not with fasting insulinemia (r  0.07,
P  0.27), after adjustment for sex, age, and total body
fat. Furthermore, no correlations with adjusted 2-h
glycemia (r  0.04, P  0.55) or insulinemia (r 
0.10, P  0.12) during the OGTT were found. Before
testing whether additional adjustment for liver fat mod-
ulated the relationships of fasting glycemia with SHBG
levels and to avoid overadjustment, we ﬁrst searched for
a parsimonious model. In a stepwise regression model
including the parameters sex, total body fat, age, SHBG
levels, and additionally liver fat, the latter three were
determinants of fasting glycemia. In a multivariate
model including these three parameters, the relation-
ship between circulating SHBG and fasting glycemia
was signiﬁcant (r  0.14, P  0.04).
SHBG levels did not correlate with measurements of
insulin secretion from the OGTT (r  0.09, P  0.16) or the
ivGTT (r  0.07, P  0.35), adjusted for sex, age, total
body fat, and insulin sensitivity estimated from the OGTT.
In contrast, positive correlations between circulating
SHBG with insulin sensitivity estimated from the OGTT
(r  0.14, P  0.037) and measured by the clamp (r  0.15,
P  0.057), adjusted for sex, age, and total body fat, were
found. Prior to the inclusion of liver fat in these models,
again stepwise linear regression analyses were performed.
In these models, circulating SHBG was not a determinant
of insulin sensitivity (OGTT, P  0.88; clamp, P  0.63).
We then investigated whether circulating SHBG impacts
on insulin sensitivity independently of adiponectin and
fetuin-A levels, parameters that were found to determine
insulin sensitivity and incident diabetes (40–44). In multi-
variate regression models, we ﬁrst found that both adi-
ponectin and fetuin-A were independent determinants of
TABLE 1
Subject characteristics at baseline and at follow-up in all 225 subjects
Parameter Baseline Follow-up P value
Sex (male/female) 90/135 90/135
Age (years) 47 (19–69) 48 (20–70) 0.0001
Body wt (kg) 86.2 (52.5–144.7) 84.0 (52.0–142.8) 0.0001
Waist circumference (cm) 96.5 (63.0–135.0) 92.0 (66.5–131.5) 0.0001
BMI (kg  m
2) 29.0 (19.4–43.5) 27.9 (18.9–42.9) 0.0001
Total body fatMRT (kg) 24.9 (4.0–61.0) 21.9 (0.2–57.5) 0.0001
Visceral fatMRT (kg) 2.59 (0.25–9.73) 2.04 (0.15–10.72) 0.0001
Liver fatMRS (%) 3.10 (0.16–30.88) 2.09 (0.00–23.21) 0.0001
HPA score 8.13 (3.510–11.00) 8.50 (5.32–11.38) 0.0001
VO2max (ml  min
1  kg
1)* 24.5 (9.5–54.1) 25.0 (2.0–47.1) 0.03
Fasting glucose (mM) 5.17 (4.33–7.42) 5.11 (4.11–7.31) 0.0012
2-h glucose (mM) 6.67 (4.17–11.17) 6.39 (3.50–13.39) 0.004
Fasting insulin (pM) 50 (19–373) 43 (14–175) 0.0001
2-h insulin (pM) 395 (47–2,132) 310 (37–3,112) 0.0001
Insulin sens.OGTT (arb. units) 11.7 (1.6–32.1) 13.2 (2.4–39.2) 0.0001
Insulin sens.Clamp (mol  kg
1  min
1  pM
1)§ 0.057 (0.008–0.347) 0.065 (0.021–0.267) 0.047
Insulin secretionOGTT (pM/mg/dl) 109 (25–2,346) 110 (16–9,197) 0.28
Insulin secretionivGTT (pM)§ 6,937 (1,731–16,162) 7,152 (2,527–26,462) 0.54
hs-CRP (mg/dl) 0.12 (0.01–2.31) 0.08 (0.01–1.78) 0.001
SHBG (nM) 29.8 (7.2–283.0) 33.6 (9.0–287.0) 0.0001
Adiponectin (g/ml) 12.0 (3.0–53.0) 14.0 (4.0–117.2) 0.0001
Fetuin-A (g/ml) 258 (126–478) . .
Data represent unadjusted medians (range). Differences between baseline and follow-up were tested using the matched-pairs t test. MRT,
magnetic resonance tomography; MRS, magnetic resonance spectroscopy; HPA, habitual physical activity. *Available in 200 subjects at
baseline and at follow-up. §At baseline available in 172 subjects, and at follow-up available in 47 subjects.
TABLE 2
Correlations between circulating SHBG and fat compartments at baseline adjusted for sex and age in the subgroup of 118 subjects
Visceral fat Liver fat Circulating SHBG
rPrP r P
0.72 0.0001 0.35 0.0002 0.22 0.016 Total body fat
0.54 0.0001 0.28 0.0022 Visceral fat
0.40 0.0001 Liver fat
Total body and visceral fat were measured by MR tomography, and liver fat was measured by
1HMR spectroscopy.
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turned out to be an independent determinant of insulin
sensitivity, both estimated from the OGTT and measured
by the clamp (Table 3).
Relationship between the rs1799941 SNP in SHBG
with metabolic characteristics. In our population, the
SNP rs1799941 in SHBG was in Hardy-Weinberg equilib-
rium (
2 test; P  0.97) and the allele frequency of the
minor A allele was 0.29. In agreement with Perry et al. (3),
we found that carriers of the minor A allele had higher
circulating SHBG, independently of sex, age, and total
body fat (P  0.025). This relationship became stronger
after additional adjustment for the important determinant
of circulating SHBG, liver fat (P  0.007). Also in agree-
ment with Perry et al. (3), we found no signiﬁcant rela-
tionships of the SNP with fasting glycemia or insulinemia,
insulin sensitivity, estimated from the clamp and the
OGTT, or measurements of insulin secretion (all P  0.18).
DISCUSSION
Two recently published studies using the Mendelian ran-
domization approach provided strong evidence that circu-
lating SHBG is directly involved in the pathogenesis of
type 2 diabetes, both in men and in women (2,3). This may
now help to more deeply address the complex, but doubt-
lessly important, role of sex hormones in the natural
history of the disease. However, prior to this, it is critical
to understand which mechanisms involved in the patho-
genesis of type 2 diabetes regulate circulating SHBG.
Certainly genetic variability in SHBG is a candidate. Al-
though the studies addressing this issue consistently found
the SNPs in SHBG to be associated with SHBG levels in
humans, the variants explained merely about 2% of the
variance in circulating levels of the protein (2,37). There-
fore, other mechanisms appear to be more important in
the regulation of circulating SHBG.
Selva et al. convincingly showed that glucose- and
fructose-induced hepatic lipogenesis, via decrease in cel-
lular hepatocyte nuclear factor-4, inhibits hepatic SHBG
expression in vitro and in mice (20). On the basis of the
fact that hepatic lipogenesis is strongly associated with
fatty liver in humans (19), we could recently show that
elevated liver fat content strongly correlated with circu-
lating SHBG in humans (30). In the present study, we
could replicate these ﬁndings in an independent group of
subjects. In univariate cross-sectional analyses, both, total
body and visceral adiposity correlated negatively with
circulating SHBG. However, when liver fat was included in
these analyses, the relationships became nonsigniﬁcant.
Using data from our longitudinal lifestyle intervention
study, we were then also able to investigate which param-
eters were associated with a change in circulating SHBG.
In agreement with the cross-sectional data, we found that
subjects having the largest decrease in total body fat,
visceral fat, or liver fat also had the largest increase in
SHBG levels during the intervention. Furthermore, in
multivariate analyses, also in the longitudinal data,
changes in total body or visceral fat were no more
associated with a change in circulating SHBG, but a
change in liver fat still correlated negatively with a change
in SHBG levels. These ﬁndings suggest that any correlation
observed between measures of total body and visceral
adiposity with SHBG levels is most probably driven by
liver fat.
What is the novel impact of these ﬁndings on future
research or interventions? From a pathophysiological as-
pect, these data support that interventions speciﬁcally
inhibiting or reducing hepatic lipogenesis may represent
the most promising tools to increase SHBG levels in
humans. So far, recommendation of diets with a low
glycemic index or a low carbohydrate content may be the
most efﬁcient and safe intervention. Although it is still not
solved whether such diets are superior to other nutritional
approaches to reduce body weight (45,46), there is clear
evidence that they are very efﬁcient in improving dyslipi-
demia and parameters of glucose metabolism, even when
the effect on body weight was small (45,47). Now it would
be very important to study whether a low glycemic index
diet is particularly effective in decreasing liver fat and
increasing circulating SHBG in humans.
Besides carefully investigating parameters increasing
SHBG levels, our aim of the present study was to investi-
gate by which mechanisms SHBG levels impact on type 2
diabetes. First, we were very surprised at learning from
TABLE 3
Determinants of insulin sensitivity in multivariate linear regression models
Covariates
Insulin sensitivityOGTT Insulin sensitivityClamp
Estimate  SE P Estimate  SE P
Model 1
Female sex 0.16  0.04 0.0001 0.17  0.04 0.0001
Age 0.004  0.130 0.98 0.06  0.13 0.66
Total body fat 0.58  0.09 0.0001 0.60  0.09 0.0001
Model 2
Female sex 0.11  0.04 0.01 0.08  0.04 0.06
Age 0.29  0.14 0.04 0.27  0.14 0.06
Total body fat 0.47  0.09 0.0001 0.50  0.09 0.0001
Adiponectin levels 0.25  0.09 0.007 0.38  0.09 0.0001
Fetuin-A levels 0.76  0.20 0.0002 0.47  0.21 0.027
Model 3
Female sex 0.06  0.04 0.19 0.03  0.05 0.46
Age 0.30  0.14 0.03 0.26  0.14 0.07
Total body fat 0.42  0.09 0.0001 0.47  0.09 0.0001
Adiponectin levels 0.22  0.09 0.01 0.37  0.09 0.0001
Fetuin-A levels 0.83  0.20 0.0001 0.50  0.21 0.018
SHBG levels 0.16  0.06 0.0096 0.14  0.06 0.029
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associated with both circulating SHBG and the prevalence
of type 2 diabetes, were not associated with any measures
of type 2 diabetes related traits in population-based stud-
ies. It may well be that different assays used to measure
insulin and glucose between the studies may have made
the data difﬁcult to interpret. Furthermore, it is possible
that the effect of the SNPs on circulating SHBG is small.
This is supported by the little variance in SHBG levels that
can be explained by the SNP rs1799941, which showed the
strongest association with SHBG levels (3,37). Conse-
quently, also in our study, this SNP was not associated
with insulinemia, glycemia, or measures of insulin sensi-
tivity or insulin secretion.
However, we found a signiﬁcant negative correlation of
circulating SHBG with fasting glycemia. Interestingly, no
correlation with fasting insulinemia was observed. These
ﬁndings argue against the hypothesis that hyperinsulin-
emia is responsible for the decline in SHBG levels in
humans and support that glucose may be involved in the
regulation of SHBG production. Alternatively, it is also
possible that SHBG may impact on hepatic gluconeogen-
esis, the most important determinant of fasting glycemia
(48) in humans. This hypothesis is supported by the fact
that the correlation between circulating SHBG and fasting
glycemia remained statistically signiﬁcant, even after ad-
justment for fasting insulinemia (P  0.002) or liver fat.
Regarding whole-body insulin sensitivity, we provide
novel data that circulating SHBG was a determinant of this
parameter, which was estimated from the OGTT and
measured by the clamp, independently of established
humoral factors, the adipokine adiponectin (40,43,49) or
the hepatokine fetuin-A (41,50), that are associated with
liver fat and regulate whole-body insulin sensitivity. This
ﬁnding suggests that SHBG may be involved in the regu-
lation of whole-body insulin sensitivity via mechanisms
that do not necessarily involve adiponectin or fetuin-A
signaling. Interestingly, circulating SHBG did not correlate
with measurements of whole-body insulin sensitivity after
further adjustment for liver fat. This is in contrast to the
results regarding fasting glycemia. A conservative inter-
pretation of these data would result in the conclusion that
circulating SHBG may impact on hepatic glucose produc-
tion but not on insulin-mediated glucose disposal. In the
future studies in humans, applying tracer methods may
help to precisely address this question.
Furthermore, no correlation of circulating SHBG with
insulin secretion was found. For these analyses, we used
two measures of insulin secretion, the insulinogenic index
obtained from the OGTT, representing an estimate of
glucose- and incretin-induced insulin secretion, and the
ivGTT, a powerful tool to measure glucose-induced insulin
secretion. These data argue against a major role of circu-
lating SHBG in the pathogenesis of 	-cell dysfunction in
humans.
Altogether, when summarizing the data in the literature
in the ﬁeld of SHBG research and our present data, the
following hypothetical picture emerges regarding causes
and metabolic consequences of circulating SHBG in hu-
mans (ﬁgure 1): First, also in our replication cohort, SHBG
levels strongly correlated with liver fat in cross-sectional
and in longitudinal analyses, supporting that conditions
regulating fat accumulation in the liver affect circulating
SHBG. Second, because the SNP rs1799941 of SHBG is
associated with SHBG levels independently of liver fat,
genetic variability in SHBG directly appears to regulate the
circulating levels of the protein. Third, the relationships of
SHBG levels with whole-body insulin sensitivity are most
probably explained by liver fat. Fourth, a signiﬁcant rela-
tionship of SHBG levels with fasting glycemia, which was
independent of liver fat, was found. Because fasting gly-
cemia is most strongly affected by hepatic glycogenolysis
and/or gluconeogenesis (48), our ﬁndings suggest that
SHBG may have direct effects on hepatic glucose produc-
tion. Increased hepatic glucose output in concert with a
	-cell defect might explain the association of circulating
SHBG and SHBG genetic variants with type 2 diabetes.
In conclusion, using cross-sectional and longitudinal
data in an independent group of subjects, we can now
support our previous ﬁndings that high liver fat most
strongly associates with low circulating SHBG. Possible
mechanisms by which high circulating SHBG prevents the
development of type 2 diabetes involve regulation of
fasting glycemia but not alteration of insulin secretory
function.
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